Cambrex expansion

Cambrex Corp. has announced the completion of a $50 million expansion of its facilities in Charles City.


CHARLES CITY — Cambrex Corp. has announced the completion of a $50 million state-of-the-art production and warehousing expansion at its cGMP Charles City site.

The investment in capacity and capabilities was made in reflection of strong market demand for small-molecule active pharmaceutical ingredients (APIs) and high utilization of Cambrex’s existing large scale assets, according to a press release from the company.

“There is high demand for U.S.-based suppliers with large scale cGMP contract manufacturing capacity and world class quality systems,” said Steve Klosk, CEO of Cambrex.

“We have invested over $125 million at the Charles City site since we acquired it in 1991,” he said, “and believe that this expansion, combined with a very talented and experienced team, provides an ongoing foundation for our customers’ small molecule product manufacturing needs while supporting our goal of bringing our customers’ products to market quickly.”

The new 7,500-square-foot multipurpose manufacturing facility will initially add a total of 70 cubic meters of reactors along with agitated filter dryers to provide a flexible, multi-purpose configuration. The facility complements the three existing large scale manufacturing facilities at the Charles City site.

The 36,000-square-foot cGMP warehouse provides general storage for 2,720 pallets and segregated refrigerated storage for 360 pallet spaces with monitored temperature and humidity controls. The facility employs a barcode system for automated bin location and has a dedicated sampling room with appropriate extraction and handling for flammable materials.

Additionally, a further 7,500-square-foot manufacturing shell has been constructed which will be fitted out to customer specifications.

Cambrex’s Charles City facility sits on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.

The facility is one of a limited number authorized by the U.S. Drug Enforcement Administration to import narcotic raw materials at commercial scale.

For more information, visit


Load comments